certainly is by far the most important factor determining which threedimensional shapes may possibly be assumed. Whether the shape of the hormone molecule in the act of entering a cell, of changing the permeability of membranes, or of reacting with other molecules (receptors) within a biochemical mechanism leading to a biological effect has anything in common with a preferred conformation in a crystal or in aqueous solution, is highly questionable. More probably, it is dependent on the spatial requirements of the particular cell wall constituents or receptor-molecules.
With these last statements we have entered the realm of the bioehernist and biologist. Very much is known about over-all actions of hormones on organisms in vivo and tissues in vitro, but comparatively very little about the biochemical mechanisms which are influenced and the receptor-molecules involved. Some hormones seem to act upon the DNA of chromosomes ( directly ?) , inducing particular genes to liberate their information, making it available for the synthesis of RNA and of specific proteins and enzymes 7 • Others may influence an enzyme system which is involved in the conversion of ATP into cycloadenylic acid, a process concomitantly stepping up the rate of glycolysis and TPNH-production which is essential for energetic and synthetic activities in the cell 8 a. In this latter case the specificity observed within a·given set of hormones would be a function of different molecular characteristics not of the biochemical mechanism which is influenced, but of the cell walls which have to be transgressed.
Direct actions of hormones on enzymes are, however, still not unequivocally established (for a discussion see ref. 7) . Further possibilities include interactions with cell membranes ( or with membranes of sub-cellular structures) leading to specific changes ofthe permeability ofsuch membranes which may account for the observed hormonal activity. A good example is provided by vasopressin which has been demonstrated to react with cell walls in a manner well defined by a number of chemical parameters 8 b. This Ieads to a series of basic questions: what are we really comparing when we are assaying two chemically distinct compounds in a given set of biological assa ys ? Are we comparing their action on the same biochemical mechanisms, or are we triggering different ones which give the same observable biological effect? Are we certain that differences in resorption, enzymatic degradation and transport mechanisms (through cell walls) do not seriously affect our observations?
I would like to stress the point that the best we can do at present is to compare the primary structure of polypeptides with over-all biological effects. Our investigations are forestalled with great chemical and biological ignorance which may invalidate any conclusions on a molecular basis at which we might choose to arrive. The present approach has certainly been extremely successful in finding new products for therapeutical use, demonstrating its inherent ethical qualities. It is entirely insufficient, however, from the viewpoint of molecular biology, and a great amount of labour will be required before weshall be able to recognize the code contained in the amino-acid sequence and to understand the "languages" of the receptor-molecules.
At this point I should like to emphasize the important röle which synthetic chemistry will have to play in this effort. Synthesis is the only means at hand to introduce chemical changes at will into particular parts ofpeptide 266 A chain.
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H·Gly-Ile-Val-Glu-Glu-Cys-Cys-Ala-Scr-Val-Cys-Ser-Leu-Tyr-Glu-Leu-Glu-Asp-Tyr-Cys-Asp·OH , / H· Phe-Val-Asp-Glu-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala·OH Thr-Ser-Ileu Thr-Ser-Ileu Thr-Ser-Ileu Thr-Gly-Ileu Ala-Ser-Thr Ala-Gly-Val
Amino-acid residues are abbreviated essentially with the first three letters of their trivial name 12 • When written with a capitalletter, they denote the natural stereoisomer, otherwise cn. (lower-case Ietter) the unnatural (o-)isomer (glycine is abbreviated as Gly). Hetero-atoms ofside-chain functions arenot shown, substituents on such groups are located above or below the 0 ~ symbol for the amino-acid. They are meant to replace -H (in -NH2 , -OH, and -SH) or -OH (in side-chain -COOH). The same holds true for substituents on the a-NH 2 group :I: &5 (lcft-hand side of chain) and for a-COOH (right-hand side of chain), these substituents appearing at the sidcs of thc amino-acid symbol. Thus, the symbol H·Cys·OH means L-cysteine, ::; H ·His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Glu-Asp-Phe-Val-Glu-Try-Leu-Met-Asp- Thr·OH   1  2  3  4  5  6  7  8  9  1 0  11  12  13  14  15  16  1 7  18  19  20  21  22  23  24  25  26  27 28 29 Figure 2 . Hormones of the pancreas: glucagon (from porcine pancreas) 12 • 13 • 24 POLYPEPTIDE HORMONES for biological actlvity; all the fragments obtained by enzymic digestion seem to be inactive. Further knowledge will have to await alteration of the n1olecule at specific points by sy.nthetic means.
Oxytocin, vasopressin, vasotocin
Whereas the hormones of the pancreas which influence carbohydrate metabolism in a somewhat antagonistic manner exhibit very great chemical differences, the posterior pituitary elaborates hormones which are chemically related to one another but produce dissimilar effects. We are faced with the fact that peptide hormones may be endowed with considerable specificity which is connected with structural details (for a discussion see refs. 25 and 26). Investigations in this field have been greatly stimulated and facilitated by synthetic approaches, the first ones being due to the school of du Vigneaud 27 . Typical for the chemistry of these hormones is a chain of 9 amino-acids with two residues of hemi-cystine in positions 1 and 6 joined by a disulphide bridge. The heterodetic macrocycle thus produced contains 20 atoms in the ring and is similar in size to the one encountered in the A-chain of insulin ( residues 6 to 11). Ox_.vtocin acts mainly on the smooth muscle ofthe uterus and the mammary gland, and is able to depress avian blood pressure. Pressor and antidiuretic activities are negligible. This pharmacological behaviour seems to be closely related to the presence of aliphatic amino-acid residues (isoleucine and leueine) in positions 3 and 8.
Exchange of these two residues for phenylalanine and arginine or lysine reduces the oxytocic properties very markedly, and effects on blood pressure and diuresis typical of vasopressin are produced.
We would expect the replacement of the non-polar amino-acid Leu < 8 > by a basic residue tobe responsible for this strong change of activity. Nevertheless, the smaller difference between the non-polar amino-acids Ile < 3 > and Phe < 3 > also plays a definite role in determining the type of action. An analogue of oxytocin and vasopressin, vasotocin, containing Ile < 3 > of oxytocin and Arg < 8 > of vasopressin was first prepared by synthesis 36 and subsequently shown tobe a compound regulating osmolarity in cold-blooded vertebrates and birds 37 . Its oxytocic activity is about 1/6 that of oxytocin and its pressor activity (rat) about 3 times less than that of Arg< 8 >-vasopressinl, 13 . Many synthetic analogues of oxytocin and vasopressin have been prepared27· 38 • From this work it can be concluded that activity depends .on the presence of a number of structural details, like size of the heterodetic ring, intactness of the C-terminal tripeptide chain etc., again demonstrating a very appreciable degree of specificity which does not fall short of that displayed by other groups of compound, e.g. steroid hormones 25 • 2 6 • Oxytocin was found tobe a chelating agent for Cu 2 +. An examination of the chelation properties ( titration, spectra, comparison with copper-binding by desamino-oxytocin, Phe < 2 >-oxytocin and simple glycine peptides) has given results which may be interpreted as indicating that the N-terminal amino group and 3 peptide nitrogens are the points of attachment of the metal ion. The chelate thus seems to be of the ordinary biuret-type 39 • Very little is known about the relationship between the conformation of oxytocin in aqueous solution and its biological activity. Ressler 40 has reported experimental conditions for producing a "denaturation" with concomitant loss of activity. Treatment with alkali results in intermolecular disulphide interchange which Ieads to inactive polymers, but the loss of activity after treatment with 7N urea at pH 8·0 and 4·3 (much less at 4·3) might be attributed to a change of conformation, because strong urea solutions are known to alter the three-dimensional structure of proteins. However, as the author states: " ... the possibility of chemical change should be ruled out before this inactivation in urea is ascribed to change in the spatial configuration of the oxytocin molecule".
Adrenocorticotropin and the melanophore-stimulating hormones
Turning our attention to these hormones ofthe anterior (and intermediate) pituitary we agairr find (as in the case of oxytocin and vasopressin) striking similarities of chemical structure clearly differentiating them as a group from other hormones. The most obvious feature common to all of the hormones listed in Figure 4 is the heptapeptide sequence -Met-Glu-His-PheArg-Try-Gly-(included in the frame).
This heptapeptide sequence is partly responsible for one activity which all of these compounds (including ACTH) have in common and exert on the melanocytes of amphibia causing expansion 9f the melanophores and darkening of the skin 41 -43 • A synthetic preparation of the heptapeptide in question (containing glutamine in place of glutamic acid) 44 exerts a high degree of corticotropin-releasing activity on isolated hypophyseal tissue in vitro 45 (this result has been confirmed with the heptapeptide containing the free y-carboxyl of glutamic acid) 46 • It also displays an activity on melanophores 44 which is about 100,000 times less (2·8 X 10 5 Ufg) in the in vitro assay 47 than purest preparations of cx-MSH (.._,2 X 10 10 U/g) 48 • Similar low, but definite, activity is shown by a number of synthetic polypeptides containing the sequence His-Phe-Arg-Try-Gly (3 X 10 4 U/g) 49 or analogues thereof. The fact that (in this low range) activity is elicited also by analogues containing n-amino-acids (e.g. His-phe-Arg-Try-Gly, 3·4 X 10 5 U /g) 50 would suggest that the "receptor" responsible for melanophore expansion reacts rather unspecifically against such high overdosage. Nevertheless, a great amount ofwork has been expended on the elucidation of the structural requirements of this activity (see ref. 1); many of the peptides examined are listed in Fzgure 7.
If the pre()ence of oc-and ß-MSH in warm-blooded vertebrates is not only
H·Ser-Tyr---Ser-Met-Glu-His-Phe-Arg-Try-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro· R Ac·Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Try-Gly-Lys-Pro-Val· NHa H·Asp-Ser-Gly-Pro-Tyr-Lys-Met-Glu-His-Phe-Arg-Try-Gly-Ser-Pro-Pro-Lys-Asp·OH H·Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg--Try-Gly-Ser-Pro-Pro-Lys-Asp·OH tobe regarded as an evolutionary relict but as being physiologically meaningful, we will have to search for other activities of these compounds. Some possibilities are indicated by very recent investigations on ß-MSH as a neural transmitter substance in cats 62 and on the action of (X.-MSH in stimulating the activity of the thyroid gland of guinea pigs 63 • For further studies it would be highly desirable to have an ample amount ofsynthetic material at hand, because it would be suretobe free oftraces of other hormones which might be present in a preparation isolated from natural sources. A synthesis of <X-MSH insmall amounts has been reported 64 • The purity of this synthetic material, however, has been questioned 65 ; the only preparation on a somewhat larger scale is that of an analogous, substituted tridecapeptide (Figure 7 , No. II) which possesses full melanophoretic activityss.
The demand for synthetic <X~MSH can now be filled due to two new methods developed in my laboratories. They both utilize new combinations of protecting groups which may easily and selectively be split from the intermediates without causing darnage to the peptide chain and loss of activity. The first one 67 ( Figure 5 ) allows a Straightforward synthesis of (X.-MSH utilizing intermediates and methods we had developed for the synthesis of ß 1 -24 -corticotropin (see below). The second one 68 ( Figure 6 ) yields an intermediate tridecapeptide with a free <X-amino group which lends itself to the introduction of a variety of Noc-acyl groups besides acetyl. The yields are consistently good. In cantrast to other preparations 64 , activity of our synthetic material does not deteriorate on storage. 
in pyridine* O- ACTH-ln this hormone structural elements of a-MSH (viz., the tridecapeptide chain of a-MSH without the acetyl and amide groups) are combined with a C-terminal hexakosa-peptide chain (26 amino-acid residues in specific arrangements) to produce peptides with 39 residues. During their work on ACTH, Bell and his co-workers 51 were able to isolate, besides ß-corticotropin (Figure 3 ), 7 other, chemically very similar, active compounds.
I t is not certain whether some of these are artefacts resulting from the isolation procedure, whether they simply reflect genetic differences of the population of swine from which the pituitaries were gathered, or whether they are meant to elicit qualitatively different hormonal activities. · The main biological action of corticotropin seems to be that on the adrenal cortex, both protein syrithesis 78 and synthesis of specific steroids (ii) Peptides with a low activify (less than .-..1% of the corresponding parent product)
Ac·Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Try-Gly·OH H·Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Try-Gly·OH H·Met-Glu-His-Phe-Arg-Try-Gly·OH NH 2
I
Z·Ser-Met-Glu-His-Phe-Arg-Try-Gly·OH NH 2
H·Ser-Met~Glu-His-Phe-Arg-Try-Gly·OH All of these activities could be reasonably explained by an effect of ACTH on protein synthesis, including the synthesis of specific enzymes. This, tagether with the observation that ACTH causes an increase of the ribonucleic acid within adrenal cells 83 , could be interpreted as an action of ACTH on the genes responsible for the synthesis of the proteins in question. _ Apparently, the N-terminal amino-acid (Ser) or amino-acids (Ser, Tyr) are necessary for biological activity 89 , whereas C-terminal amino-acids are less so 90 • Biologically active peptides containing 28 and more amino-acid residues of the N-terminus have been isolated from peptic digests 51 and degradative evidence has been produced to suggest that a peptide containing the N-terminal24 amino-acids displays a high degree of activity. It contains all of the basic residues of corticotropin, suggesting that these amino-acids are responsible for the activity measured.
Further insight into structure-activity relationships is strongly dependent on synthesis. Figure 10 shows the peptides synthesized in the last two years by different groups ofworkers. Our own group has concentrated on developing new methods and combinations of protecting groups for peptide synthesis H-!Scr-1 Tyr I Ser i-Metf-GfuTH.is-1 Phe I Arg I Try I Gly I LysTPro-rvaTTGiy ,--Lys I Lys I Arg which allow the production of such peptides in especially good yields and in a most versatile manner. The synthetic products and further analogues will have tobe tested in many different assay procedures in ordcr to reveal qualitative and quantitative differences against ACTH. Before more work has been invested in this project, it is certainly too early to draw any definite conclusions.
Kallidin and bradykinin
The existence of bradykinin and its polypeptide nature have first been demonstrated by Rocha e Silva 97 • The pure nonapeptide may be isolated from plasma treated with trypsin 98 or with snake venom (Bothrops jararaca) 99 • The closely related decapeptide, kallidin 10 ( one additional Lys at the N-terminal), is produced by the action of a specific enzyrne, kallikrein, on plasma 100 • 101 • The conversion ofkallidin 10 to bradykinin (kallidin 9) is effected by a variety of enzymes occurring in plasma; Figure 11 illustrates the interrelationship of the two peptides.
Pharmacological actions of the two peptides include action on smooth muscle (slow contraction of guinea pig ileum; oxytocic action at very low concentrations), lowering of blood pressure, enhancemen t of blood flow and capillary permeability, induction of activity of sweat glands, etc.l 03 • 1 M. The relatively short duration of oxytocic action is due to destructive enzymes which may be inhibited by cysteine (destruction of angiotensin cannot be inhibited by this means) 105 (Figure 12 ) have been reported. Octapeptide analogues ofbradykinin having no Pro in position 7 (numbers according to kallidin 10) may be taxed as inactive (III is active only at a dose of 50,000 times that of bradykinin); however, when Pro< 4 > is missing, the octapeptide is only 100 times less active (isol. guinea pig ileum). C-terminal-Pro-Phe-Arg·OH seems to be essential for activity. Exchange of C-terminal -Arg·OH for citrulline and histidine (XI, XII), ofN-terminal H·Arg-for citrulline (IX), and ofboth arginine residues for diaminobutyric acid or citrulline (VIII, X) lowers activity rather strongly, indicating a strong dependence of the activitics tested on the presence of Arg in these positions. A complete reversal of sequence, leaving Arg < 2 >, Pro < 4 >, Phe < 6 >, Pro < 8 > and Arg < 9 > in their original positions, eliminates activity (VII). The situation with Ser < 7 > is not dear as documented by a comparison of compounds (XIV, XV and XVI).
Activity of compounds XX and XXI (related to B 17-22 of insulin) has been taken as indicative of a particular unspecijicity of peptides with biological activity 25 b. This argumentloses much of its validity in view of the fact that peptides more closely related to bradykinin (e.g. III, VII, and others) elicit a similarly small amount of activity. Certainly, even if these compounds really do act upon the same receptors as the natural products, it is not permissible a priori to treat the response of a cell preparation to such overwhelmingly different concentrations (1 :10 5 to 1 : 10 7 ) as being specifically related to the physiological one. """""" """ """ 
Angiotensin and hypertensin
The kidneys produce and store a specific enzyme called renin 119 • 125 , which is able to catalyse the cleavage of the decapeptide, angiotensin I, from a precursor protein (angiotensinogen) found in the rx. 2 -globulin fraction ofplasma 117 -119 • This (apparently inactive) decapeptide is further degraded by a converting enzyme present in plasma 122 to the inactive dipeptide histidyl-leucine and the active octapeptide angiotensin II (hypertensin II). Species differences involve the exchange-of Ileu < 5 > for the structurally closely related, and physiologically equivalent 11 Val < 5 > (Figure 13 ). The isolation of angiotensin from blood is so difficult and gives such low yields that detailed studies of pharroacological and physiological action were only possible after the preparation of larger amounts by synthetic means 117 • A closely related synthetic derivative 117 with a higher rate of oxytocic to pressure action 126 has recently become available for therapeutical use (Hypertensin-CIBA®, No. II, Figure 15) .
The biological action mainly studied until now is the enhancement of blood pressure 117 • 118 • A number of clinical observations support the view that angiotensin is by far superior over catecholamines in the medication ofshock ofvarious origin (refs. 127-131 roay serve to illustrate this point).
Other effects of angiotensin include iron-incorporation (Fe < 59 >) into red blood cells 132 , and a qualitatively similar effect to that of vasopressin on water and salt excretion in diabetes insipidus 133 • 134 • This latter effect Ieads us to one of a purober of possible physiological actions of the renin-angiotensin systero. It is believed that angiotensin serves to regulate kidney function as a locally acting tissue horroone 117 -119 • 125 • More recent evidence points also to a stimulation of the zona glomerulosa of the adrenals followed by enhanced excretion of aldosterone 125 • 135 • This effect has been confirmed for human beings and is not produced by norepinephrin136. It is, however, too early to decide whether the stimulation of aldosterone production is a physiological effect of angiotensin or not.
Synthesis of analogues of angiotensin in the author's laboratories ( Figures  14 and 15) and by Page and Buropus and their co-workers (Figure 16 ) has given us a great amount of insight into the structural requireroents for biological activity.
Ac·cording to Figure 14 , the asparaginyl < 1 > analogues ofVal < 5 >-angiotensin II (I) and of Val < 5 >-angiotensin I (II) display an almost equal potency to enhance blood pressure in the nephrectomized rat. This is most probably due to cleavage of histidyl-leucine from II by the enzyme converting it to the active octapeptide (I). Obviously, if this explanation is acceptable, III can equally weil be converted to I by this enzyme, whereas IV and V cannot (due to the inability of converting enzyme to split the Phe-Pro and the Phe-NH 2 bonds). Whether VI is cleaved by converting enzyme to an inactive form of I (with C-terminal n-phenylalanine) or not, is still a matter of question: in any case, n-phenylalanine in position 8 renders the decapeptide VI inactive. bromide as well as on the isolated rat uterus (oxytocic activity) 141 • The asparaginyl analogue (li) is as active as Val< 5 >-angiotensin II (I) in the first pressure assay but elicits only about 50 per cent activity in the second one, indicating a methodical difference which has to be borne in mind when comparing the other data (from here onward, parallelism is satisfactory). The more pronounced difference in oxytocic activity between II and I is worth mentioning .
.Alteration rif position No. 1 reveals a rather low specificity connected with the first residue. Asp(NH 2 ) may be replaced by Gly or removed altogether without reducing activity by more than SO per cent (III, IV). Most interesting compounds are V and Va, the n-and L-ß-asparatyl analogues of I. (Figure 15 ) may be converted to a mixture of diastereoisomers (V and V a) by transpeptidation and partial racemisa tion of Asp < 1 >. This is achieved by heating aqueous solutions ofl or li at 100° (Figure 17) . Unexpectedly, the pressure activities of both ß-compounds are considerably higher than that of the natural product (1). This is probably due to retarded degradation by plasma enzymes 142 b. Position No. 2 reveals greater specificity. The hexapeptide (VI) is almost inactive, a finding at variance with that on a similar peptide in the Ile < 5 >-angiotensin II series (Figure 16 , No. V). It is surprising to see that it is probably not only the basicity connected with the side chain of arginine which is necessary for producing activity, but that a steric element also is involved (nitrogen on the S-carbon atom ?) . This statement is suggested by the strong activities of VII (not appreciably basic, due to nitro-substitution) and VIII (nitrogen on S-C) as compared to IX (nitrogen on E-C).
I or II
The comparison seems tobe permissible in spite ofthe fact that IX contains Leu in position 5, because XI is reasonably active. Turning to the two residues with hydrophobic side chains, Val < 3 > and Val < 5 >, we find indications of a certain difference of specificity: the Leu < 3 > analog is fully active (XII), whereas a significant decrease was observed with the Leu < 5 > analogue (XI).
Conceming position 4, our conclusions are different from those of Page and co-workers 143 • These authors state that one ofthe minimal requirements for activity is a tyrosine residue in position 4. This was deduced from a comparison of the two compounds Nos. V and VII (Figure 16 ). The hexapeptide (V, Figure 16 ) showed a higher activity than our hexapeptide (VI, Figure 15) ; this activity was, despite its being only 2·3 per cent of the activity of I (Figure 16 ), assumed to be significant and characteristic of the receptor; replacement of Tyr< 4 > by Phe< 4 > (as in VII, Figure 16 ) produced complete inactivation, suggesting that the hydroxyl group was of greatest importance. It seems to be dangerous, however, to draw conclusions from quantitative differences at such a low level of activity, as surmised by the fact that the corresponding Phe < 4 > analogue of angiotensin li (XIII, Figure 15 ) elicits full 10 per cent of the activity of the Tyr < 4 > compound (II, Figure 15 ). This clearly demonstrates that the -OH group of Tyr (t) is notaminimal requirement.
Turning again to Figure 15 , we find that chain length is also essential, an additional tyrosine residue next to the original one lowering activity very appreciably (XIV). How essential steric details are, is demonstrated by XV which is inactive because of the replacement of L-tyrosine (Tyr) by its n-isomer ( tyr) 144 Nli.
- The Säo Paulo group 145 has subjected our I I to photo-oxydative inactivation, destroying the imidazole portion of the His < 6 >-residue: activity is also abolished (XVI, Figure 15) .
Whereas nothing is known about the specificity of position 7 (Pro), we do know that phenylalanine with a free carboxyl group is an essential feature of position 8. Amide formation (V, Figure 14) and esterification (XVII, Figure 15 ) reduces activity to 3 per cent and 10 per cent, respectively. Compound XX (Figure 15 ) which lacks Phe< 8 > and compound IX (Figure 16 ) in which Phe < 8 > is replaced by Ala ( 8 ) are both inactive; this is also true for XIX (Figure 15 ) which has n-phenylalanine in place of the L-isomer and shows only 0·2 per cent activity compared with SO per cent for the heptapeptide IV (Figure 15 ). Even such a slight alteration as substitution by bromine in the p-position of the phenyl ring reduces ac6vity to SO per cent (XVIII, Figure 15 ). The compounds of Figure 16 have been prepared by Page et al. 143 • Most of the results have just been discussed. The considerations applying to the comparison of VII with V are also valid for VIII. Interestingis the strong enhancement of oxytocic activity over pressor action in the Arg< 1 >-analogue (IV). It seems possible that this compound would activate similar receptors as are activated by kallidin 10 and kallidin 9.
Conformational aspects of angiotensin-Experiments on reversible denaturation
( change of optical rotation) and concomitant loss of activity by treatment with strong solutions ofurea and arginine have been reported 143 • 146 • Whether these observations reflect a change of conformation (from a biologically active to an inactive conformational isomer) or are simply due to strong adducts with urea or arginine which decompose only very slowly on dilution (the released quantities being quickly degraded by enzymes before becoming active) is still a moot point. The hydroxyl group of tyrosine has been shown 287 to dissociate with a normal pK-value and normal heat and entropy of dissociation 146 which seems to exclude the participation in any intramolecular hydrogen-bonds stabilized by special conformations. (Figure 18) , showing that chelation is accompanied by a stepwise loss of protons: at first 2 are liberated (Zn 2 +, Cu 2 +), these are followed by 2 (Cu 2 +) or 3 (Zn 2 +) other protons. The Zn-chelate is active like angiotensin when applied intraveneously. As in the case of insulin, one might debate whether angiotensin acts upon the receptor in the "free" or in a chelated state, because metal ions could be picked up in the body. Chelation has also been observed with other metal ions, e.g. Fe 3 +, Co 2 + etc. 147 and might possibly have some connection with the iron-transport activity 132 Substance P Extracts of intestine and brain showing neurotropic and musculotropic activities have been prepared by von Eulerand Gaddum 148 a. These extracts have been partially purified 148 b; the active compounds appear to be peptides. Recent work has led to a further purification of the musculotropic peptide from intestine 103 • 149 -151 ; the most active preparation has been isolated from bovine brain and contains (in agreement with the results of Vogler 150 ) 13 different amino-acids 151 • This is at variance with the findings of Franz et al. 149 • The musculotropic action of the peptide isolated from brain is easily distinguishable from that of bradykinin: it contracts the isolated guinea pig ileum and hen's coecum (threshold dose 0·5 ng/ml), the isolated rat uterus only in doses 100 to 200 times larger, and lowers the blood pressure of the rabbit (bradykinin is inactive on the hen's coecum 10 \ its relative activities on guinea pig's ileum and rat's uterus are inverse). The pair bradykinin-substance P is another example of the high specificity of polypeptides. 30,000 U /mg, from intestine149 100,000 Ufmg, from intestine150 150,000-300,000 Ufmg, from brainu 1 Figure 19 . Musculotropic factor of substance P 1 0 3 ,152 289
Metal binding

CONCLUDING REMARKS
Biological activity of polypeptides is apparently very specifically related to structure and configuration of these compounds (primary structure). It remains to be demonstrated whether particular conformations (secondary and tertiary structures) which are stable in the solid state or in solution are necessary for activity. However, to be able to assume a conformation demanded by the receptor, certain features of primary structure must needs be present. The chains of biologically active polypeptides contain portians which are essential for activity, others which are not. The correct amino-acid sequence within the active site seems to be necessary to activate the right receptors, although variations at certain points appear tobe more permissible than at others (specificity requirements of particular positions in angiotensin II probably become more exacting in the following sequence: Asp (l) ~ Val< 3 > < Val< 5 > < Arg< 2 > z Tyr< 4 > <:: Phe< 8 >). Chain length outside ofthe active site sometimes is necessary for producing quantitatively a maximum effect: these "inactive" sites probably also contribute to transport properties, to reduction of enzymatic viability etc. The "inactive" site probably has to 290 depend on specific amino-acid sequences tobe able to fulfil its task, although the requirements might be less stringent.
The examination of sequence-activity relationships must be carried out at a high Ievel of activity; this is the only way to be reasonably sure that one is dealing with specific effects and not with non-specific ones (a point tha t has often been neglected) .
I t is very tempting to compare amino-acid sequence with other linear codes, for example with a sequence of letters in written language. Whether a "language" understandable for all receptors will issue from our endeavour, or whether every receptor or certain groups of receptors have different "languages", is rather irrelevant at the moment, but adds quite an amount of intellectual incentive to the problems presented here.
